Dextran is used clinically for plasma volume expansion, improvement of blood flow and
thromboprophylaxis, but has been associated with untoward side effects …

A prospective study of dextran-induced anaphylactoid reactions (DIAR) in 5745
gynaecological and obstetric patients who received dextran 70 solution intravenously while …

Dextran-60 is widely used as a colloid volume substitute and for thromboprophylaxis. In
order to avoid the most dangerous complication associated with dextran, the dextran …

Prevention of deep vein thrombosis, thromboembolism, and fatal pulmonary embolism is a
major consideration in the perioperative period. Dextran, a polysaccharide with an average …

All spontaneous reports to the manufacturer and to WHO's database INTDIS regarding
adverse reactions to clinical dextran after preinjection of dextran 1 and to dextran 1 alone …

At a meeting held in July 2005, the Blood Products Advisory Committee of the US Food and
Drug Administration (FDA) addressed the problem of serious and lifethreatening …

Dextran 40 Anaphylaxis Page 1 736 ANESTHESIA AND ANALGESIA . . . Current Researches
VOL. 54, NO. 6, Nov.-DEc., 1975 p1/ CHOICE In each issue of the Journal an article particular …

The incidence of dextran-induced anaphylactoid/anaphylactic reactions (DIAR) was
investigated after hapten inhibition employing two different modes of administration of …

In an open prospective study the prevention of dextran-induced anaphylactic reactions
(DIAR) by hapten inhibition was investigated in 29 252 patients. Forty-nine hospitals in …

In an open, prospective multi-center study prevention of dextran-induced anaphylactic
reactions (DIAR) was attempted by intravenous injection of 20 ml dextran 1, 15%, Mw 1000 …